BHVN earnings: next report 2026-08-10, real EPS beat/miss history, analyst consensus Buy, P/E -2.60. Updated 2026-07-23.
Biohaven (BHVN) Research Hub
Biohaven (BHVN) trades on NYSE, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 12.71 USD (-15.27%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -2.60, market cap 1.57B. This hub links to the full technical, earnings and options research available for BHVN.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NYSE, US |
| Last close | 12.71 USD (-15.27%) |
| 52-week range | 11.13 USD – 18.24 USD |
| Trend regime | Range |
| 14-day RSI | 40.6 (Bearish) |
| Trailing P/E | -2.60 |
| Market cap | 1.57B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-10 |
Available research for BHVN
Covered Call on BHVN: how it works, illustrative setup around the real 12.71 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on BHVN: how it works, illustrative setup around the real 12.71 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on BHVN: how it works, illustrative setup around the real 12.71 USD price, max profit/loss, breakeven and when to use it. Educational.
BHVN technical analysis: range, last 12.71 USD, RSI 40.6, 52w range 11.13 USD–18.24 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is BHVN in?
Biohaven (BHVN) is classified under Healthcare (Biotechnology), listed on NYSE, US.
Is BHVN in an uptrend or downtrend?
As of 2026-09-11, BHVN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is BHVN's trailing P/E ratio?
BHVN's trailing P/E is -2.60, with a market cap of 1.57B. See the earnings research page for full valuation detail.
When does BHVN next report earnings?
BHVN is next scheduled to report earnings on 2026-08-10, with a consensus EPS estimate of -0.77 USD.